SCHEMBL236407

SCHEMBL236407

CC([N])Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2556849 0.79
SCHEMBL7725 0.79
SCHEMBL137217 0.72
SCHEMBL5728116 0.72
Hydrogen Sulfide SCHEMBL11755188 0.72
SCHEMBL17222435 0.72
SCHEMBL5438089 0.72
SCHEMBL6967583 0.72
SCHEMBL9065633 0.72
Ammonia Solution, Strong SCHEMBL3894177 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3858387-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS Seagen Inc. (US) 2021-08-04 EP disclosed
EP-3778917-A2 MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS F. Hoffmann-La Roche AG (CH) 2021-02-17 EP disclosed
US-10918735-B2 Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-02-16 US disclosed
US-20200347149-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEAGEN INC. 2020-11-05 US disclosed
US-10808039-B2 Monomethylvaline compounds capable of conjugation to ligands SEATTLE GENETICS INC. (US) 2020-10-20 US disclosed
US-10584181-B2 Methods of making and using multispecific antibody panels and antibody analog panels GENENTECH, INC. (US) 2020-03-10 US disclosed
US-20190338045-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEAGEN INC. 2019-11-07 US disclosed
US-10414826-B2 Monomethylvaline compounds capable of conjugation to ligands SEATTLE GENETICS, INC. (US) 2019-09-17 US disclosed
US-20190255187-A1 SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-08-22 US disclosed
EP-3498289-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS Seattle Genetics, Inc. (US) 2019-06-19 EP disclosed
US-20060182751-A1 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use GENENTECH, INC. (US) 2006-08-17 US disclosed
WO-2006060533-A2 CONJUGATES OF 1, 8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY GENENTECH, INC. (US) 2006-06-08 WO disclosed
WO-2006034488-A2 CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES GENENTECH, INC. (US) 2006-03-30 WO disclosed
US-20050276812-A1 maytansinoid drug moieties covalently linked by a linker to an antibody which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors; cancer GENENTECH, INC. (US) 2005-12-15 US disclosed
WO-2005117986-A2 ANTIBODY DRUG CONJUGATES AND METHODS GENENTECH, INC. (US) 2005-12-15 WO disclosed
WO-2005101017-A1 MASS SPECTROMETRY OF ANTIBODY CONJUGATES GENENTECH, INC. (US) 2005-10-27 WO disclosed
US-20050238649-A1 Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases SEATTLE GENETICS, INC. (US) 2005-10-27 US disclosed
US-20050232929-A1 Mass spectrometry of antibody conjugates GENENTECH, INC. 2005-10-20 US disclosed
WO-2005081711-A2 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEATTLE GENETICS, INC. (US) 2005-09-09 WO disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed